Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tideglusib - AMO Pharma

Next Previous
Drug Profile

Tideglusib - AMO Pharma

Alternative Names: AMO-02; NP-031112; NP-12; Nypta; Zentylor

Latest Information Update: 18 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Neuropharma
  • Developer AMO Pharma; Brock University; Noscira; Population Health Research Institute; Venca Research
  • Class Anti-inflammatories; Antidementias; Behavioural disorder therapies; Naphthalenes; Neuroprotectants; Small molecules; Thiadiazoles
  • Mechanism of Action Glycogen synthase kinase 3 beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myotonic dystrophy; Progressive supranuclear palsy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Myotonic dystrophy
  • Phase II Arrhythmogenic right ventricular dysplasia
  • Preclinical Duchenne muscular dystrophy
  • No development reported Autism spectrum disorder
  • Discontinued Alzheimer's disease; Progressive supranuclear palsy

Most Recent Events

  • 15 Sep 2025 AMO Pharma plans meetings with UK MHRA and Health Canada
  • 15 Sep 2025 AMO Pharma plans to meet with the US FDA for NDA submission in Myotonic Dystrophy in quarter four of 2025
  • 15 Sep 2025 Adverse events data from REACH CDM X phase II/III trial in Myotonic dystrophy were released by AMO Pharma

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top